Melanotan 1 (Afamelanotide)

Skin, Hair & Aesthetics
Phase 4
FDA Approved

Melanotan 1 (Afamelanotide) is a synthetic version of the natural skin-darkening hormone alpha-MSH. It is FDA-approved as Scenesse, a subcutaneous implant for treating EPP, a rare genetic condition causing extreme sun sensitivity. It is also commonly used via injection or nasal spray for tanning.

Last updated February 22, 2026
52 PubMed-Verified Studies
Popular
Research-Driven Dosage Reports
RouteSubcutaneous (SC) · Nasal Spray
Dose0.08–0.16 mg/kg (SC injection)
FrequencyDaily for 10 days (clinical trials)
Duration10–28 days (study protocols)

Based on published research literature.

Swiss Chems|Exclusive Offer
Coupon
10%
Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Overview of Melanotan 1 (Afamelanotide)

Selectively activates MC1R receptors on melanocytes, stimulating eumelanin production for photoprotection without significant sexual side effects.

Skin / cosmetic

Selectively binds MC1R on melanocytes, stimulating eumelanin (brown/black pigment) synthesis.

Provides photoprotection by increasing melanin density before UV exposure, reducing sunburn risk.

Photoprotection

Increases pain-free sun exposure time in EPP patients, an FDA-approved indication.

May reduce UV-induced DNA damage, with potential skin cancer prevention.

Immune / inflammation

MC1R activation on immune cells, with anti-inflammatory effects reported in some studies

Read Full Melanotan 1 (Afamelanotide) Dosage Guide

Research-backed dosing protocols, timing, and administration details

Browse more in this category

Skin, Hair & Aesthetics